This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Takeda Pharmaceutical Company Ltd
Drug Names(s): bortezomib, MLN341, LDP 341, PS-341
Description: Proteasome inhibition is a novel approach to cancer treatment. Multiple myeloma is a particularly challenging form of cancer to treat successfully.
Although Velcade is best known for its inhibition of the ubiquitin-proteasome biological pathway, experiments show that it also inhibits proteins related to this pathway including IkB/NF-kB, p53, and the cyclin-dependent kinase inhibitors p21 and p27. Velcade should be thought of as influencing cellular processes regulated by these proteins in such a way that inhibits cell growth signaling pathways, induces apoptosis, and inhibits the expression of important cellular adhesion molecules.
Deal Structure: Velcade was originally developed by ProScript, Inc. ProScript was acquired by LeucoSite, which was subsequently acquired by Millennium.
In July 2003, Millennium and Ortho Biotech, a subsidiary of Johnson & Johnson, partnered to develop and market Velcade. Ortho Biotech will market the drug outside the U.S. for all indications, while Millennium retains rights to market Velcade in the U.S. and to co-market Velcade in certain European markets. Ortho Biotech will help Millennium with funding ongoing and new clinical trials of Velcade, and with worldwide regulatory applications. The partnership could be worth up to $750 million for MLNM.
Financial Terms: Upfront payment of $15m on execution of agreement. Potential for $125m in clinical, regulatory and sales milestones related to multiple myeloma. Up to $330m in clinical and regulatory milestones based on success in solid and other hematological tumors. In addition, up to $65m additional sales milestones on achievement of...See full deal structure in Biomedtracker
Partners: Johnson & Johnson
Additional information available to subscribers only: